Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock grants and stock option grants and recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017

Employee and director stock and stock option grants:
Research and development	$	36,625	$	40,072	$	70,752	$	56,720
General and administrative		138,954		191,014		278,265		340,040
Total stock-based compensation	$	175,579	$	231,086	$	349,017	$	396,760

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

A summary of stock option activity is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options			Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2017		53,172		$	65.50
Granted		8,000		$	11.70
Expired		(1,550	)	$	349.20
Forfeited		(2,096	)	$	19.30
Outstanding at June 30, 2018		57,526		$	52.10

Exercisable, June 30, 2018		32,131		$	72.90		7.82	$	—
Unvested, June 30, 2018		25,395		$	25.70		8.73	$	—

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of restricted stock activity is as follows:

Outstanding non-vested restricted stock at December 31, 2017	38,000
Granted	—
Vested	(12,666	)
Outstanding non-vested restricted stock at June 30, 2018	25,334